Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585961 · ClinicalTrials.gov registry record
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
A clinical trial, sponsored by Biosense Webster.
- Completed
- Registry status
- 511
- Enrollment target
NCT01585961: Completed study, sponsored by Biosense Webster.
NCT01585961 is a clinical trial that has completed, run by Biosense Webster. The registered enrollment target is 511 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01585961 has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- 511 participants
- Enrollment target
Study Summary
This is a prospective, interventional, observational, unblinded, single-arm, multicenter registry of younger and older subjects with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation.
Primary Outcome
The fluoroscopy time will be measured for each phase (access, mapping, ablation, and validation) of the procedure and summed to derive the total time.
Interventions
- DEVICE Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-07 |
What the finished NCT01585961 record still lists
NCT01585961 is an observational study that tracks outcomes without assigning an intervention. The registered 511 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter) is the first listed.
NCT01585961 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01585961 about?
NCT01585961 is a clinical study titled "NAVISTAR® THERMOCOOL® SF Catheter: Observational Study". This is a prospective, interventional, observational, unblinded, single-arm, multicenter registry of younger and older subjects with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation.
What is the current status of trial NCT01585961?
This trial is currently completed. The enrollment target is 511 participants. The study started on 2012-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01585961?
The interventions under investigation include: Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter) (DEVICE).
Who is sponsoring clinical trial NCT01585961?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia